NCT07030036

Brief Summary

This study aims to identify cognitive problems in adults with multiple sclerosis (MS). MS can affect memory, thinking speed, and spatial skills, which may impact daily life and work. We will use simple and proven tests to check for these difficulties and see how they affect quality of life. The study will include about 60 patients followed at the neurology day hospital.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 19, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

July 15, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 15, 2025

Completed
Last Updated

June 19, 2025

Status Verified

June 1, 2025

Enrollment Period

4 months

First QC Date

June 12, 2025

Last Update Submit

June 12, 2025

Conditions

Multiple SclerosisCognitive DysfunctionNeuropsychological TestsQuality of Life

Outcome Measures

Primary Outcomes (1)

  • Prevalence of cognitive impairment in patients with multiple sclerosis, assessed by validated cognitive tests (CSCT, RL/RI-16, Figure de REY, HAD scale, SF-12).

    12 months

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of adult patients (18 years and older) diagnosed with multiple sclerosis for at least six months according to the 2017 McDonald criteria. These patients are currently receiving disease-modifying treatments and are followed at the neurology day hospital of CH Gonesse.

You may qualify if:

  • Patients aged 18 years or older
  • Diagnosed with multiple sclerosis (MS) for at least 6 months according to the 2017 McDonald criteria (SFSEP)
  • Receiving disease-modifying treatment and followed in the neurology day hospital of CH Gonesse

You may not qualify if:

  • \- Under 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

France

Gonesse, France, France

Location

MeSH Terms

Conditions

Multiple SclerosisCognitive Dysfunction

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2025

First Posted

June 19, 2025

Study Start

July 15, 2025

Primary Completion

November 15, 2025

Study Completion

November 15, 2025

Last Updated

June 19, 2025

Record last verified: 2025-06

Locations

FR(1)